10-Q: IN8bio Prioritizes Pipeline, Reduces Workforce in Q3 2024

IN8bio announced a pipeline prioritization and workforce reduction in September 2024, focusing on INB-100 development and suspending INB-400 trials.

Summary

• IN8bio reported a net loss of $24.3 million for the nine months ended September 30, 2024, compared to a net loss of $22.4 million for the same period in 2023.
• The company's cash balance was $4.0 million as of September 30, 2024, with an additional $11.6 million raised through a private placement in October 2024.
• A pipeline prioritization in September 2024 led to the suspension of INB-400 development and a 49% workforce reduction.
• The company expects its current cash, along with proceeds from the private placement, to fund operations through December 2025.
• There is substantial doubt about the company's ability to continue as a going concern for the next 12 months.
• Research and development expenses were $13.4 million for the nine months ended September 30, 2024, compared to $12.3 million for the same period in 2023.
• General and administrative expenses were $10.0 million for the nine months ended September 30, 2024, compared to $10.4 million for the same period in 2023.
• The company incurred $1.1 million in severance and related charges due to the workforce reduction.
• The company sold 3,479,623 shares of common stock under its ATM program, resulting in net proceeds of $3.8 million.
• The company amended certain Series A warrants, reducing the exercise price to $0.45 per share and extending the termination date to October 4, 2025.

Sentiment

Score: 4

Explanation: The document reveals significant financial challenges and a strategic shift, including a workforce reduction and the suspension of a clinical trial. While there are some positive aspects, such as the private placement and focus on INB-100, the overall sentiment is negative due to the going concern warning and the need for further capital.

Positives

• The company has secured additional funding through a private placement in October 2024.
• The company is focusing its resources on its most promising product candidate, INB-100.
• The company has taken steps to reduce operating costs through a workforce reduction and executive pay cuts.
• The company has amended certain Series A warrants, potentially increasing the likelihood of their exercise.

Negatives

• The company has incurred significant operating losses and has an accumulated deficit of $115.5 million.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has suspended further development of INB-400, a key product candidate.
• The company has reduced its workforce by approximately 49%, which may impact its ability to execute its strategy.
• The company's cash balance is low, and it is relying on additional funding to continue operations.

Risks

• The company may not be able to raise additional capital when needed, which could force it to delay or discontinue its research and development programs.
• The company's product candidates are in early stages of development and may not be successful in clinical trials or obtain regulatory approval.
• The company faces significant competition from other pharmaceutical and biotechnology companies.
• The company's manufacturing process is complex, and it may encounter difficulties in production.
• The company relies on third-party contractors for manufacturing and clinical trials, and their failure to perform could harm the company's business.
• The company is dependent on key personnel, and the loss of their services could impede its progress.
• The company may be subject to product liability claims, which could be costly and harm its reputation.
• The company's ability to raise capital may be limited by applicable laws and regulations.
• The company's outstanding warrants may not be exercised, and the company may not receive any cash proceeds from any exercise of warrants.
• The company's ability to raise capital may be adversely impacted by potential worsening global economic conditions, interest rates, inflation expectations, the U.S. federal election, recent disruptions to and volatility in the credit and financial markets in the United States and worldwide resulting from public health crises and geopolitical tensions, such as the Israel-Hamas war and the Russia-Ukraine war.

Future Outlook

The company expects its existing cash and the net proceeds from the 2024 Private Placement to fund its operations through December 2025. The company plans to continue clinical development of INB-100 and seek strategic collaborations for its GBM program and earlier-stage assets.

Management Comments

• The company announced a plan to optimize its resource allocation through a pipeline prioritization.
• The executive management team and the Board agreed to an 11% reduction in their cash compensation.

Industry Context

The company is operating in the competitive field of immuno-oncology, where many companies are developing novel cell therapies. The company's focus on gamma-delta T cells is a relatively new approach, and the company faces challenges in demonstrating the safety and efficacy of its product candidates.

Comparison to Industry Standards

• The company's cash burn rate is high, which is typical for clinical-stage biotechnology companies.
• The company's decision to prioritize its pipeline and reduce its workforce is a common strategy for companies facing financial challenges.
• The company's reliance on third-party manufacturers and CROs is also typical for companies of its size.
• The company's clinical trial results for INB-100 are encouraging, but further data is needed to confirm its efficacy.
• The company's decision to suspend the INB-400 trial is a setback, but it is not uncommon for companies to discontinue programs that do not show sufficient promise.

Management Changes

Stakeholder Impact

• Shareholders face the risk of losing all or part of their investment due to the company's financial challenges.
• Employees have been impacted by the workforce reduction.
• Customers (patients) may experience delays in the development of new therapies.
• Suppliers and creditors may face increased risk due to the company's financial instability.

Next Steps

• The company will continue clinical development of INB-100.
• The company will seek strategic collaborations for its GBM program and earlier-stage assets.
• The company will continue to monitor patients previously treated in the INB-200 and INB-400 clinical trials.
• The company expects to complete additional enrollment in the INB-100 trial in 2025.
• The company expects to present updated data on INB-100 at the American Society of Hematology Annual Meeting in December 2024 and other medical meetings throughout 2025.

Key Dates

Keywords

IN8bio, INB-100, INB-400, gamma-delta T cells, clinical trials, biopharmaceutical, workforce reduction, private placement, warrants, pipeline prioritization, severance, operating expenses, research and development, going concern